Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x100
Organisation › Details

Carmat S.A. (ALCAR)

A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, composed of the implantable bioprosthesis and its portable external power supply system to which it is connected, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States. The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader. The first physiological artificial heart:given its size, the use of highly biocompatible materials, its unique self-regulation system and its pulsatile nature, the CARMAT total artificial heart could, assuming the clinical trials are successful, potentially save the lives of thousands of patients each year with no risk of rejection and with a good quality of life. A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million. Strongly committed, prestigious founders and shareholders: Matra Défense SAS (subsidiary of the Airbus Group), Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, ALIAD (Air Liquide’s venture capital investor), CorNovum (an investment holding company held 50-50 by Bpifrance and the French State), the family offices of Pierre Bastid (Lohas), of Dr. Antonino Ligresti (Santé Holdings S.R.L.), of the Gaspard family (Corely Belgium SPRL and Bratya SPRL) and of M. Pierre-Edouard Stérin (BAD 21 SPRL), Groupe Therabel as well as the thousands of institutional and individual shareholders who have placed their trust in CARMAT. *

 

Period Start 2008-06-30 established
Products Industry cardiovascular device
  Industry 2 artificial heart
Persons Person Piat, Stéphane (Carmat 201812 CEO)
  Person 2 d’Arbonneau, Pascale (Carmat 201812– CFO before Econocom International + GSK 1999–2016)
     
Region Region Île-de-France (region)
  Country France
  Street 36 avenue de l’Europe
  City 78941 Vélizy-Villacoublay
  Tel +33-1-3945-6450
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2018-12-17)
     
    * Document for �About Section�: Carmat S.A.. (10/12/20). "Press Release: Carmat Is Granted €13 Million in National Innovation Funding to Conduct the EFICAS Study in France". Paris.
     
   
Record changed: 2022-04-12

Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

More documents for Carmat S.A. (ALCAR)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2022 650x300




» top